dEEGtal Insights reinforces governance for its next phase of growth
dEEGtal Insights, a Wyss–supported startup developing artificial intelligence solutions for neurology and psychiatry, continues to advance its clinical and strategic trajectory. The company has reached several important development milestones and just announced the appointment of Ann Bunnenberg to its Board of Directors as an independent member.
A seasoned medical device entrepreneur, investor, lawyer, and business advisor, Ann Bunnenberg brings extensive experience in neurotechnology, product development, and international commercialization. Her expertise aligns closely with dEEGtal’s mission to unlock the clinical value of brain signals through artificial intelligence. She will support the company as it expands collaborations with hospitals, research institutions, and technology partners.
“I am excited to join the Board of dEEGtal at such an important moment in the company’s evolution,” said Ann Bunnenberg. “The team is developing an innovative approach to interpreting EEG data that has the potential to significantly improve how neurological conditions are detected and managed. I look forward to supporting the company as it brings this technology to clinicians and patients.”
Enhancing clinical decision-making through AI-driven brain signal analysis
dEEGtal is developing an AI-powered platform designed to enable machines to interpret brain signals, starting with electroencephalography (EEG). Built on large-scale datasets collected across leading European and American clinical centers, the company’s approach combines advanced signal analysis with clinical data to unlock new diagnostic and predictive capabilities.
Its first clinical application focuses on improving care pathways following a first seizure, with the goal of enabling faster and more accurate identification of patients at risk of epilepsy. By supporting clinical decision-making in time-sensitive environments, the technology aims to improve both speed and precision of care.
Expanding collaborations
dEEGtal has already validated its software on datasets collected from seven epilepsy centers as part of an academic research project conducted prior to the company’s incorporation.
Building on this foundation, the company is now expanding its clinical collaborations across Europe and the United States. Ongoing and upcoming studies include:
- A study with the Hospitals of Basel, evaluating the platform in a real-world first seizure unit setting
- A study at Vall d’Hebron Hospital in Barcelona, targeting approximately 350 patients, to assess performance in emergency care and early triage decision-making
- A collaboration with the University of Texas Medical Branch (UTMB) in Galveston, which will lead U.S.-based clinical trials
Across these initiatives, dEEGtal expects to generate pre-clinical evidence based on approximately 2,000 patient datasets.
Strengthening governance to support growth
The appointment of Ann Bunnenberg reflects dEEGtal’s commitment to reinforcing its governance as the company scales its technology and expands its clinical and commercial footprint. Her addition to the Board of Directors supports the company’s transition toward broader deployment and market readiness.
An ambitious roadmap toward clinical and commercial expansion
Looking ahead, dEEGtal plans to initiate clinical trials in the United States, a key step toward becoming a commercial-stage company in a major healthcare market. The company is currently raising a CHF 4–5 million seed round, expected to close in the second quarter of 2026. Beyond epilepsy, dEEGtal aims to leverage its AI platform and large-scale brain data models to address additional neurological and psychiatric conditions, expanding into new patient populations and clinical applications.